For research use only. Not for use in humans.

Depatuxizumab (Anti-ERBB1 / EGFR / HER1)

Synonyms: EGFR,ERBB1 Cat.No.A2887 Purity:99%

Depatuxizumab (anti-ERBB1/ EGFR / HER1) is a humanized monoclonal antibody (MoAb) against the human epidermal growth factor receptor (EGFR) with antineoplastic activity. MW: 144.54 KD.

Quality Control

Batch: A288701 Purity: 99% Protein concentration: 10.205mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	EGFR/ErbB1	HER2/ErbB2	ErbB3	ErbB4	mutant EGFR	Others
Saracatinib (AZD0530)	312	+++					c-Src,c-YES,LCK
Canertinib (CI-1033)	51	++++	+++
AG-490	132	+					JAK2 (V617F)
CP-724714	109		++
WZ4002	34	++++
Sapitinib (AZD8931)	50	+++	+++	+++
CUDC-101	23	+++	++				HDAC,HDAC1,HDAC6
AG-1478	100	+++
PD153035 HCl	20	++++
Pelitinib (EKB-569)	11	+	+				Src,MEK/ERK,Raf
AEE788 (NVP-AEE788)	16	++++	+++		+		c-Abl,FLT1,c-Fms
AC480 (BMS-599626)	12	++	++		+
AP26113-analog (ALK-IN-1)	5					++	ALK,IGF1R,INSR
WZ3146	2	++++
Allitinib tosylate	19	++++	+++		++++
Rociletinib (CO-1686)	37	++
Varlitinib	8	+++	++++
Icotinib (BPI-2009H)	11	+++
TAK-285	5	++	++		+		MEK1,Aurora B,LCK
WHI-P154	11	+++					Src,VEGFR,JAK3
Daphnetin	4	+					PKA,PKC
PD168393	6	++++
CNX-2006	2	++				++
Tyrphostin 9	2	+					PDGFR
AG-18	1	+
Icotinib Hydrochloride	0	+++
HS-10296 hydrochloride	3					++++
MTX-531	0	++					PI3Kα
Avitinib maleate	0	+++				++++	BTK
limertinib	0					++++
AG 825	0		+				PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine	1	+
AST-1306	10	++++	+++		++++
ErbB2 inhibitor	0		+		+
Tuxobertinib (BDTX-189)	3	++++	++++				RIPK2,BLK
Epertinib hydrochloride	1	++++	+++		+++
JND3229	0	+++				++	EGFR C797S
BI-4020	1					++++
Tyrphostin AG-528	0	+	+
AG 556	0	+
Canertinib dihydrochloride	8	+++	+++
EGFR Inhibitor	4	++					Microtubules
SU5214	0	+					VEGFR2
RG 13022	0	+
TQB3804	1					++++
zipalertinib (TAS6417)	5	+++			+++	++++	TXK,BMX
Pyrotinib dimaleate	6	++	++
PD153035	14	++++
AG 494	0	+
AG 555	1	+
Theliatinib (HMPL-309)	0	+++				++
Avitinib (Abivertinib)	3					++++	JAK3,BTK
Lazertinib (YH25448)	9	++++				++++	Del19,L85R
Lifirafenib (BGB-283)	8	++				+	WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816)	6	++				++
Zorifertinib (AZD3759)	7	++++
CL-387785 (EKI-785)	5	++++
Poziotinib (NOV120101, HM781-36B)	37	+++	+++		++
AZ5104	6	++++			+++		ACK1,BLK,BRK
AV-412 free base	0	++++	++			++++
HER2-Inhibitor-1	1		✔
WZ8040	3	✔
Genistein	38	✔					topo II
Rezivertinib	1	✔
BDTX-1535	0	✔
Falnidamol	1	✔
BLU-945	1	✔
(S)-Sunvozertinib ((S)-DZD9008)	1	✔
CH7233163	1	✔
Licochalcone D	1	✔					NF-κB,PARP,Caspase
Furmonertinib Mesylate (AST2818, Alflutinib)	3	✔					CYP3A4
(Rac)-JBJ-04-125-02	0	✔
Tyrphostin AG30 (AG30)	0	✔
AG-1557	0	✔
AG99	0	✔
MTX-211	2	✔					PI3K
RG14620	0	✔					ABCG2
Almonertinib (HS-10296)	4					✔
Cyasterone	1	✔
Norcantharidin	5	✔					c-Met
Naquotinib(ASP8273)	2	✔
EAI045	3					✔
Olmutinib (BI 1482694)	6	✔					BTK
Butein	3	✔
Chrysophanic Acid	3	✔					mTOR
EGCG ((-)-Epigallocatechin Gallate)	42	✔					DNMT,telomerase,FASN

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Depatuxizumab (anti-ERBB1/ EGFR / HER1) is a humanized monoclonal antibody (MoAb) against the human epidermal growth factor receptor (EGFR) with antineoplastic activity. MW: 144.54 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25731184/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1471999-69-5
Molecular Weight	144.54
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07209241	ACTIVE_NOT_RECRUITING		Recurrent Glioblastoma	University of Pennsylvania	2025-12-03	PHASE1
NCT07642024	RECRUITING	Drug: BL-B01D1\|Drug: Osimertinib\|Drug: Carboplatin\|Drug: Pem	Non-small Cell Lung Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	2026-07-24	PHASE2; PHASE3
NCT07183189	RECRUITING	Drug: SHR-A2009 ; Aumolertinib\|Drug: Aumolertinib	Non-small Cell Lung Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	2025-10-30	PHASE3
NCT06053099	RECRUITING		Non Small Cell Lung Cancer; EGFR Activating Mutation; EGFR DEL19; EGFR L858R	Intergroupe Francophone de Cancerologie Thoracique	2024-01-22
NCT07715734	NOT_YET_RECRUITING	Drug: Cemiplimab\|Drug: Prednisone\|Drug: Sirolimus\|Drug: Cetu	Kidney Transplant Recipient; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Cutaneous Squamous Cell Carcinoma; Kidney Transplant	Washington University School of Medicine	2026-09-30	PHASE2
NCT07507188	NOT_YET_RECRUITING	Drug: Amivantamab SC + Lazertinib PO\|Drug: Amivantamab SC +	Non Small Cell Lung Cancer	Yonsei University	2026-04-06	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.